Aug 7 (Reuters) - Zimmer Biomet Holdings ( ZBH ) beat

Wall Street estimates for second-quarter profit on Wednesday,

driven by robust demand for its devices used in joint

reconstruction procedures.

Medical device makers have boosted investor expectations in

the recent quarters as more people, especially older Americans,

opt for non-urgent surgeries such as hip and knee replacements.

Peer Stryker Corp ( SYK ) last month raised its annual

profit outlook betting on robust demand for its hip and knee

implants.

Zimmer, however, cut its annual revenue growth forecast

anticipating a higher foreign currency impact. Zimmer now sees

revenue growth of 4% to 5% from a year earlier, compared to 4.5%

to 5.5% growth forecast previously.

Combined sales at Zimmer's hips and knees units came in at

$1.31 billion, shy of analysts' estimate of $1.32 billion,

according to LSEG data.

The company also saw strong sales at its unit that sells

sports medicine and trauma care products. Sales at the unit rose

6.1% year-over-year to $469.5 million, topping estimates of

$465.4 million.

Separately, Zimmer said on Tuesday it would acquire

OrthoGrid Systems, a privately held medtech firm to gain access

to its artificial intelligence-driven surgical guidance systems

for total hip replacement.

The hip and knee implant maker reiterated its full-year 2024

profit expectations in the range of $8.00 to $8.15 per share.

Analysts were expecting annual profit of $8.09 per share.

Zimmer's second-quarter revenue rose nearly 4% to $1.94

billion, in-line with analysts' average estimates.

On an adjusted basis, the company posted a profit of

$2.01 per share in the quarter ended June 30, topping estimates

of $1.99 per share.